Skip to main content

11-22-2022 | Dulaglutide | News


FDA clears dulaglutide for adolescents

Author: Eleanor McDermid


medwireNews: The FDA has approved extending use of dulaglutide to children and adolescents aged 10 years or older who have type 2 diabetes.

Treatment with the weekly injectable glucagon-like peptide-1 receptor agonist resulted in significant reductions in glycated hemoglobin levels, relative to placebo treatment, among young people aged 10–17 years in the AWARD-PEDS trial, published in June this year.

It did not significantly reduce weight, however.

Dulaglutide is also indicated to reduce glucose levels in adults with type 2 diabetes and to reduce the risk for major adverse cardiovascular events in those at high risk.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »